For biopharma companies that are poised to profit from COVID-19-related misfortune however, older drugs that have outlived their patent terms are not terribly helpful for the bottom line. Could this be why leading White House coronavirus advisor Anthony Fauci, MD, long-time head of NIAID, recently pooh-poohed the published chloroquine evidence as merely “anecdotal”?